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The pleoitropic effect of inflammatory 
cytokines demands complex and multi­
faceted regulation to limit collateral 
damage to normal tissue. On one level, 
inflammatory  cytokines  such  as  inter­
leukin 1 (IL­1) and IL­18 exist as in­
active zymogens that require proteolytic 
cleavage mediated by the inflammasome 
(Martinon et al., 2008). This proteolytic 
maturation acts in concert with NF­B–
dependent  transcriptional  activation  of 
genes encoding the zymogens to catalyze 
a substantial increase in the levels of se­
creted, bioactive protein. Other inflam­
matory cytokines such as tumor necrosis 
factor (TNF) and IL­6 are induced pri­
marily at the transcriptional level and, in 
the case of TNF, subject to posttranscrip­
tional messenger RNA stabilization by 
virtue of the dissociation of the mRNA­
binding  protein  tristetraprolin  from  its 
adenine­ and uridine­rich (ARE) region 
(Anderson,  2000).  Although  these  are 
well­established mechanisms of regulat­
ing proinflammatory cytokine produc­
tion,  it  is  becoming  apparent  that  an 
additional layer of complexity exists; i.e., 
signals provided by ROS.
The mitochondrion plays a critical 
role in cell survival, most prominently 
by generating the vast majority of a cell’s 
supply of adenosine triphosphate (ATP), 
but also by influencing apoptosis, cell 
cycle,  and  metabolism.  Mitochondria 
generate ATP through aerobic respira­
tion,  whereby  glucose,  pyruvate,  and 
NADH are oxidized, thus generating 
ROS as a byproduct. In normal cir­
cumstances,  the  deleterious  effects 
caused by the highly reactive nature of 
ROS are balanced by the presence of 
antioxidants,  including  glutathione, 
carotenoids,  and  antioxidant  enzymes 
such as catalase and glutathione peroxi­
dase. However, several chronic human 
diseases associated with inflammation 
are  also  characterized  by  excessive 
ROS production (Drake et al., 1998; 
Cominelli, 2004; Reuter et al., 2010). 
Perhaps not surprisingly, defective mi­
tochondria have also been implicated 
in human diseases with underlying in­
flammatory pathologies, such as diabe­
tes  mellitus  and  cardiac  dysfunction 
(DiMauro and Schon, 2003; Nisoli et al., 
2007; Patti and Corvera, 2010).
Three recent publications, includ­
ing Bulua et al. in this issue, indicate 
that  mitochondrial  ROS  (mtROS) 
act as signaling molecules to trigger 
proinflammatory cytokine production 
(Nakahira  et  al.,  2011;  Zhou  et  al., 
2011).  These  observations  provide 
much  needed  clarification  about  the 
cellular source of ROS that impacts 
the production of certain inflammatory 
cytokines. Although all three publica­
tions  underscore  the  importance  of 
mtROS­dependent signaling, they dif­
fer most notably by describing either   
inflammasome­dependent  or  inflam­
masome­independent roles for ROS.
Using  cells  from  patients  with 
TNFR1­associated  periodic  syndrome 
(TRAPS), along with a relevant mouse 
model, Bulua et al. (2011) demonstrate 
that mtROS influences the transcription 
of proinflammatory cytokines such as 
IL­6. In its most severe form, TRAPS 
manifests as episodes of fever and severe 
localized inflammation that is associated 
with “structural” mutations in TNFR1. 
These TNFR1 mutations interfere with 
down­regulation of cell surface TNFR 
expression, result in retention of the re­
ceptor within the endoplasmic reticu­
lum, confer ligand (TNF) independence, 
and prolong the cytokine response to 
lipopolysaccharide (LPS; McDermott 
et al., 1999; Simon et al., 2010; Bulua 
et al., 2011).
Bulua  et  al.  (2011)  found  higher 
baseline levels of mtROS in monocytes 
and neutrophils from TRAPS patients 
and  in  mouse  embryonic  fibroblasts 
(MEFs) engineered to express hetero­
zygous TRAPS­associated TNFR1 mu­
tations. The enhancement of ROS levels 
in the mutant MEFs correlated with an 
increase in the levels of active JNK and 
p38, a finding consistent with previous 
research linking persistent MAPK acti­
vation to manifestation of the TRAPS 
phenotype (Simon et al., 2010). Inhibi­
tion of mtROS production inhibited 
MAPK activation and production of 
IL­6 and TNF in cells from TRAPS 
patients (Bulua et al., 2011), a finding 
consistent with a previous study showing 
that ROS can inactivate MAPK phos­
phatases  (Kamata  et  al.,  2005). Thus, 
mitochondria are the cellular source of 
High levels of reactive oxygen species (ROS) are observed in chronic human 
diseases such as neurodegeneration, Crohn’s disease, and cancer. In addition 
to the presence of oxidative stress, these diseases are also characterized by 
deregulated inflammatory responses, including but not limited to proinflam-
matory cytokine production. New work exploring the mechanisms linking ROS 
and inflammation find that ROS derived from mitochondria act as signal-
transducing molecules that provoke the up-regulation of inflammatory 
cytokine subsets via distinct molecular pathways.
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lacking NLRP3, caspase­1, or IL­1R 
produce  normal  levels  of TNF  and   
IL­6 after LPS stimulation (Bulua et al., 
2011). These observations confirm that 
neither  mtROS  production  nor  the 
signals transduced by mtROS depend 
on  activation  of  the  inflammasome.   
In  a  critical  mechanistic  divergence, 
two  recent  studies  (Nakahira  et  al., 
2011; Zhou et al., 2011) identify an   
inflammasome­dependent  role  for 
mtROS (Fig. 1).
Pharmacological interventions, such 
as IL­1 antagonists, which are used to 
treat  cryopyrinopathies  caused  by  per­
turbed inflammasome activation, have 
limited  efficacy  for  the  treatment  of 
TRAPS. Although it is anticipated that 
mechanisms of reducing mtROS levels 
may be of therapeutic utility for TRAPS,   
it  remains  to  be  determined  how 
mtROS  levels  themselves  are  modu­
lated. However, some insight is provided 
by  the  observation  that  macrophages 
the  excessive  ROS  in TRAPS,  and  a 
delicate equilibrium between MAP ki­
nase and phosphatase activity defines a 
rheostat regulated primarily by the levels 
of mtROS, which in turn enables an 
inflammatory response to proceed in a 
timely and effective fashion. Notably, 
LPS­induced  IL­6  production  was  re­
duced even in healthy cells treated with 
mtROS  inhibitors,  indicating  that  this 
signaling cascade is relevant to the induc­
tion of a normal inflammatory response.
Figure 1.  Putative mechanisms of ROS-dependent proinflammatory cytokine production in normal, healthy cells. During inflammasome- 
independent proinflammatory cytokine production (left), mtROS modulates the equilibrium between positive and negative regulators, which results in an 
increase in the rate of transcription of cytokines such as IL-6. Several steps in this pathway require further investigation. Specifically, how does activation 
of TLR4 by LPS result in an increase in ROS production from an individual mitochondrion (A), and how does mtROS inhibit negative regulators (e.g., MAPK 
phosphatases) of cytokine gene transcription (B)? Inflammasome-dependent proinflammatory cytokine production (right) requires inhibition of autoph-
agy and mitophagy to increase the net amount of mtROS within the cell. The mechanism of this inhibition is unknown (C). Once mtROS accumulates, it 
activates the NLRP3 inflammasome, but the mechanism of this activation remains undefined (D). Once activated, the NLRP3 inflammasome undergoes a 
conformational change and assembles into a homooligomeric complex (one subunit is depicted) that catalyzes the activation of pro–caspase-1. In the 
case of IL-, the active p10-p20 caspase-1 heterodimer cleaves pro–IL-1 to produce a mature form that is subsequently exported from the cell. AP-1, 
activator protein 1; ASC, apoptosis-associated speck-like protein; CARD, caspase recruitment domain; DAMP, damage-associated molecular patterns; IRF, 
interferon response factor; LRR, leucine-rich repeat; PAMP, pathogen-associated molecular patterns; PYD, pyrin domain.JEM VOL. 208, March 14, 2011 419
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response? The cellular source of physio­
logically relevant ROS is also stimulus 
dependent,  as  inflammatory  signaling 
downstream of TLR ligation is depen­
dent  on  mtROS,  whereas  crystalline 
particles such as asbestos and silica re­
quire both NADPH oxidase and mtROS 
(Dostert  et  al.,  2008;  Nakahira  et  al., 
2011; Zhou et al., 2011). This under­
scores the importance of defining the 
physiologically  relevant  amount  and 
source of ROS for each class of stimuli.
Further experiments will illuminate 
whether mtROS impacts other proin­
flammatory  transcriptional  networks, 
even though it does not modulate IRF3­
dependent induction of IFN­ (Bulua 
et al., 2011). Consequently, elucidating 
how ROS signaling acquires specificity 
for any given transcriptional network is 
of  critical  importance.  Because  of  the 
highly reactive nature of ROS, its signal 
transduction properties are likely to in­
clude direct chemical modification of its 
targets  and/or  catalysis  of  enzymatic 
reactions (e.g., H2O2). Indeed, the redox 
regulator  superoxide  (SOD­1)  modi­
fies  the  redox­sensitive  cysteines  of   
caspase­1  to  modulate  its  activation 
(Meissner et al., 2008). NLRP3 and ASC 
relocalize to the mitochondria after in­
flammasome  activation  (Zhou  et  al., 
2011),  but  whether  this  relocalization 
facilitates  such  modifications  has  yet   
to be demonstrated and is much antici­
pated.  Another  important  issue  is 
whether  mtROS,  or  ROS  in  general,   
influences  the  activation  of  other  in­
flammasomes  such  as  IPAF/NLRC4 
or AIM2 inflammasomes. The observa­
tion  that  macrophages  lacking  the   
IPAF/NLRC4  inflammasome  respond 
normally to artificial induction of ROS 
and that mtROS production is dispens­
able for activation of IPAF and AIM2 
inflammasomes (Zhou et al., 2011) ar­
gues against this and raises the question 
of  how  specificity  for  the  NLRP3­ 
inflammasome is acquired. Answers to 
such challenging questions will provide 
further  refinement  of  the  model  of 
ROS­dependent proinflammatory cyto­
kine production, as well as information 
necessary for the development of novel 
therapeutic  interventions  for  ROS­
driven human diseases.
perturbation  of  basal  levels  of  auto­
phagy had a profound impact on the in­
tegrity of the mitochondria, as Beclin 
or  LC3­deficient  macrophages  gener­
ated  more  mitochondrial  superoxide 
anion radical (O2
) in the absence of 
stimulation. Thus,  autophagy  regulates 
baseline mtROS production from indi­
vidual  mitochondria  by  a  yet  to  be 
identified mechanism.
The  release  of  mitochondrial 
DNA (mtDNA) in to the cytosol after 
treatment of BMDMs with LPS and 
ATP potentiated caspase­1 activation   
(Nakahira et al., 2011). Thus, mtDNA   
is  an  additional  secondary  messenger 
that acts as a surrogate marker of mito­
chondrial  dysfunction  and  also  acti­
vates caspase­1, presumably to amplify 
the inflammatory response. This am­
plification loop depends on NLRP3, 
as NLRP3 deficiency suppressed the   
release  of  mtDNA  after  LPS  and   
ATP stimulation.
Collectively, these two investigations 
clearly  established  that  in  normal 
healthy cells the process of mitophagy 
is a critical negative regulator of inflam­
masome activation. This implies that ac­
tive inhibition of autophagy is required 
for proinflammatory signaling to pro­
ceed, for damaged mitochondria to ac­
cumulate,  for  intracellular  mtROS  to 
increase,  for  mtDNA  release,  and  for 
the NLRP3 inflammasome to be acti­
vated. Consequently, a pressing ques­
tion  is,  how  do  NLRP3­dependent 
stimuli inhibit autophagy?
The intimate relationship between 
mtROS production and proinflamma­
tory cytokine activation is now well 
established. The fact that different cyto­
kines are subjected to distinct regula­
tory  events,  simplistically  defined  as 
either transcriptional or posttranslational, 
suggests that the generality of any given 
mechanism is likely to be limited. The 
distinct  temporal  regulation  of  IL­1 
(early response) and TNF and IL­6 (late 
response)  also  suggests  that  different 
cytokines will be influenced in distinct 
ways by the production of mtROS. For 
example, are MAPK phosphatases only 
inhibited  in  the  presence  of  higher 
levels of mtROS that presumably accu­
mulate at later stages of an inflammatory 
The inflammasome does not regu­
late transcription directly, but rather is 
responsible for the activation of caspase­1, 
an enzyme responsible for the proteo­
lytic maturation of IL­1 and IL­18. 
Since  the  initial  identification  of  in­
flammasomes,  much  interest  has  been 
given to identifying the initiating events 
that lead to the assembly of these multi­
protein scaffolds. The multiplicity and 
apparent divergent nature of NLRP3­
dependent stimuli have identified this 
particular inflammasome as a focus of 
investigation. Models posited for the ac­
tivation of the NLRP3 inflammasome 
include direct interaction with cognate 
ligand,  and  conformational  alteration 
induced by secondary messengers or   
alterations in the intracellular milieu 
resulting from lysosomal rupture (Latz, 
2010). Consistent with a secondary mes­
senger model, Zhou et al. (2011) and 
Nakahira et al. (2011) demonstrate that 
after an inflammatory stimulus, the ac­
cumulation  of  damaged  mitochondria 
precipitates an increase in mtROS pro­
duction,  which  in  turn  enhances  in­
flammasome activation.
Autophagy is the process of “self­ 
digestion”  that  occurs  by  delivery  of 
self­components to the lysosomal ma­
chinery.  Mitophagy  is  a  specialized   
form  of  autophagy  that  refers  to  the 
specific  catabolism  of  mitochondria. 
Pharmacological  inhibition  of  auto­
phagy  by  treatment  of  macrophages 
with 3­methyladenine resulted in the 
accumulation of damaged mitochondria 
and  an increase in the net amount of 
mtROS (Zhou et al., 2011). IL­1 se­
cretion induced by mtROS elevation 
was abolished in Nlrp3
/ and Asc
/ 
cells, thus confirming that the NLRP3   
inflammasome is activated in a ROS­
dependent  manner.  In  bone  marrow­ 
derived macrophages (BMDMs), genetic 
deletion of the autophagy­related pro­
tein LC3B, which prevents the forma­
tion and maturation of autophagosomes, 
also enhanced caspase­1 activation and 
production of IL­1 and IL­18 in re­
sponse to the inflammasome­dependent 
stimuli LPS and ATP (Nakahira et al., 
2011). Similar results were observed after 
deletion of the critical upstream regu­
lator of autophagy, Beclin 1. In addition, 420 ROS-dependent cytokine production | Naik and Dixit
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